Syros Pharmaceuticals Inc (SYRS) Receives Consensus Rating of “Buy” from Analysts
Syros Pharmaceuticals Inc (NASDAQ:SYRS) has been given an average recommendation of “Buy” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $26.14.
A number of research firms recently weighed in on SYRS. Oppenheimer set a $28.00 target price on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 target price on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. Roth Capital began coverage on shares of Syros Pharmaceuticals in a research note on Monday, October 23rd. They set a “neutral” rating and a $15.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th.
Syros Pharmaceuticals (SYRS) traded down $0.10 during mid-day trading on Thursday, hitting $8.98. 256,648 shares of the company were exchanged, compared to its average volume of 133,275. Syros Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $24.38.
A number of institutional investors and hedge funds have recently made changes to their positions in SYRS. Schwab Charles Investment Management Inc. acquired a new position in Syros Pharmaceuticals in the second quarter valued at approximately $343,000. Rhumbline Advisers acquired a new position in Syros Pharmaceuticals in the second quarter valued at approximately $198,000. Bank of New York Mellon Corp boosted its holdings in Syros Pharmaceuticals by 157.9% in the second quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock valued at $483,000 after purchasing an additional 18,382 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Syros Pharmaceuticals by 360.5% in the second quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock valued at $366,000 after purchasing an additional 17,785 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in Syros Pharmaceuticals by 646.3% in the second quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock valued at $553,000 after purchasing an additional 29,782 shares in the last quarter. 58.02% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Syros Pharmaceuticals Inc (SYRS) Receives Consensus Rating of “Buy” from Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/14/syros-pharmaceuticals-inc-syrs-receives-consensus-rating-of-buy-from-analysts.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.